Solventum (NYSE:SOLV – Get Free Report) is one of 238 public companies in the “Surgical & medical instruments” industry, but how does it contrast to its rivals? We will compare Solventum to similar ...

Solventum (NYSE:SOLV – Get Free Report) had its price target boosted by research analysts at Mizuho from $70.00 to $82.00 in a research report issued to clients and investors on Monday,Benzinga ...

Solventum has appointed former Zimmer Biomet executive Rachel Ellingson as chief strategy and corporate development officer.

Activist investor Trian Fund Management plans to push Solventum to separate more of its businesses after the company’s $4.1 ...

Solventum surpassed fourth-quarter revenue and earnings expectations while facing challenges in segments and regulatory ...

Shares of Solventum jumped Tuesday and led S&P 500 gainers intraday after medical device maker Thermo Fisher Scientific said ...

Solventum (NYSE: SOLV) today announced it has entered into a definitive agreement to sell its Purification & Filtration1 ...

M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.

Waltham-based Thermo is buying the business from Solventum, a Minnesota-based company that spun off from manufacturing ...

Solventum's $4.1B divestment to Thermo Fisher enhances financial stability, boosts EPS, and strengthens its long-term growth ...

Solventum faces significant challenges in its turnaround, including slow-growing core businesses, share loss, and margin ...

Solventum Corp. closed 20.58% short of its 52-week high of $96.05, which the company achieved on March 26th.